Your browser doesn't support javascript.
loading
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Lancet Oncol ; 11(10): 962-72, 2010 Oct.
Article in En | MEDLINE | ID: mdl-20851682

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Thyroid Neoplasms / Cell Differentiation / Radiopharmaceuticals / Protein Kinase Inhibitors / Iodine Radioisotopes / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2010 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Thyroid Neoplasms / Cell Differentiation / Radiopharmaceuticals / Protein Kinase Inhibitors / Iodine Radioisotopes / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2010 Type: Article Affiliation country: United States